TIP: Tinengotinib In Prostate Cancer

Study Details

Full Title

A Phase 1b/2 Study Evaluating the Activity of Tinengotinib (TT-00420) in Combination with Androgen Receptor Signaling Inhibitors (ARSIs) in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)

Principal Investigator

Hannah
McManus

Protocol Number

PRO00116180

NCT ID

NCT06457919

Phase

I/II

Enrollment Status

Open to Enrollment